第五屆ADC藥物開(kāi)發(fā)峰會(huì)通知

會(huì)議基本信息：
會(huì)議名稱(chēng)： 第五屆ADC藥物開(kāi)發(fā)峰會(huì)
會(huì)議地點(diǎn)： 蘇州，中國(guó)
會(huì)議時(shí)間： 2024年3月1-2日

會(huì)議背景
截止到2023年10月，全世界范圍內(nèi)共有15款A(yù)DC藥物獲批上市。尤其是從2018年至今，在科研單位及行業(yè)的努力下，ADC藥物的臨床療效取得了重大進(jìn)展，以Enhertu為代表的ADC逐漸顯示出成為10億美元重磅炸彈的藥品趨勢(shì)，年復(fù)合增長(zhǎng)率已經(jīng)達(dá)到了40.4%。創(chuàng)新的偶聯(lián)技術(shù)平臺(tái)，優(yōu)化的DARs值，改進(jìn)的linker可以進(jìn)一步的控制ADC的精準(zhǔn)性、臨床療效、以及減少毒素副作用。在此背景下，中國(guó)的ADC藥物開(kāi)發(fā)也成功的吸引了全世界的目標(biāo)，投資，授權(quán)合作不斷。為此，我們將于2024年3月1-2日在蘇州，召開(kāi)第五屆ADC藥物開(kāi)發(fā)峰會(huì)。期待大家的出席！

會(huì)議主題：
M（主論壇）. 全球ADC市場(chǎng)動(dòng)態(tài)：投資與合作趨勢(shì)
ADC藥物開(kāi)發(fā)走進(jìn)舞臺(tái)中央
中國(guó)ADC藥物合作開(kāi)發(fā)，國(guó)際大藥廠(chǎng)押注下一個(gè)重磅炸彈賽道
ADC兼并，收購(gòu)，合作的背后驅(qū)動(dòng)力
A1. 靶點(diǎn)發(fā)現(xiàn)、轉(zhuǎn)化醫(yī)學(xué)及臨床前開(kāi)發(fā)
創(chuàng)新靶點(diǎn)及生物標(biāo)志物驗(yàn)證
ADC非臨床研究要點(diǎn)：藥理學(xué)、毒理學(xué)、安全性評(píng)價(jià)要點(diǎn)
監(jiān)管視角：ADC非臨床開(kāi)發(fā)挑戰(zhàn)
可驗(yàn)證的端到端的ADC藥物發(fā)現(xiàn)平臺(tái)
避免熱點(diǎn)靶點(diǎn)內(nèi)卷、ADC開(kāi)發(fā)的熱門(mén)方向
A2: 臨床開(kāi)發(fā)：全球化及腫瘤以外適應(yīng)癥探索
全球化多中心臨床的開(kāi)發(fā)挑戰(zhàn)
差異化臨床開(kāi)發(fā): 臨床策略提升ADC成功率
ADC聯(lián)合治療方向：與化療Combo，
超越腫瘤及血液瘤：ADC實(shí)體瘤進(jìn)展與非腫瘤適應(yīng)癥開(kāi)發(fā)
簡(jiǎn)化臨床開(kāi)發(fā)，加速推動(dòng)候選分子從實(shí)驗(yàn)室邁向臨床
A3: 下一代創(chuàng)新偶聯(lián)治療實(shí)體
新型作用機(jī)制下的新型有效負(fù)載：超越傳統(tǒng)毒素
不斷創(chuàng)新的新型偶聯(lián)治療實(shí)體
推動(dòng)XDC進(jìn)入臨床：創(chuàng)新設(shè)計(jì)以及控制開(kāi)發(fā)風(fēng)險(xiǎn)
創(chuàng)新偶聯(lián)治療實(shí)體分享：蛋白降解偶聯(lián) / 多肽偶聯(lián) / 雙抗偶聯(lián) / 雙環(huán)肽的放射性偶聯(lián) 等等
B1: 攜手共進(jìn)：MNC & 本土Biotech合作
ADC藥物更廣泛的治療窗口挑戰(zhàn)
MNC與中國(guó)本土創(chuàng)新Biotech管線(xiàn)合作開(kāi)發(fā)，開(kāi)發(fā)進(jìn)展協(xié)同挑戰(zhàn)
全球ADC藥物開(kāi)發(fā)背景下的中國(guó)機(jī)會(huì)
下一步合作趨勢(shì)：擴(kuò)大適應(yīng)癥以及推進(jìn)到一二線(xiàn)治療
出海授權(quán)合作中的風(fēng)險(xiǎn)控制、知識(shí)產(chǎn)權(quán)保護(hù)
資本視角：ADC藥物投資方向
B2: 案例展示：創(chuàng)新ADC技術(shù)平臺(tái)
全面革新ADC 設(shè)計(jì)：優(yōu)化的抗體、可裂解的連接子、創(chuàng)新的毒素
設(shè)計(jì)鏈接器以增加ADC 功效和降低毒性
使用兩種不同的雙有效負(fù)載 ADC
細(xì)胞毒素可降低藥物耐藥性
新型ADC平臺(tái)：負(fù)載多樣化
B3: 授權(quán)出海及商業(yè)化策略
從PD-1授權(quán)出海中學(xué)到的經(jīng)驗(yàn)與啟示
建立更廣泛的合作來(lái)擴(kuò)展管線(xiàn)以及開(kāi)拓海外市場(chǎng)
與海外監(jiān)管單位保持密切溝通，攜手合作方共同應(yīng)對(duì)注冊(cè)申報(bào)挑戰(zhàn)
急劇增長(zhǎng)的ADC銷(xiāo)售份額共同應(yīng)對(duì)海外市場(chǎng)商業(yè)化開(kāi)發(fā)挑戰(zhàn)
C1: 連接子 & 毒素 以及ADC的耐受性
通過(guò)接頭設(shè)計(jì): 提高功效、穩(wěn)定性并減少脫靶毒性
非內(nèi)化的ADC開(kāi)發(fā)
ADC 毒性的影響和優(yōu)化策略
最小化毒性并提高耐受性, 以最大化 ADC 的治療效果
免疫原性、旁觀(guān)者效應(yīng)或系統(tǒng)性毒素以及快速清除
C2: 選擇可靠的合作伙伴共同應(yīng)對(duì)工藝挑戰(zhàn)
確保ADC的產(chǎn)品質(zhì)量、效力
穩(wěn)健可放大的工藝、支持快速工藝轉(zhuǎn)移
如何協(xié)同小分子與大分子共同工藝優(yōu)化的挑戰(zhàn)
抗體工程化、藥物遞送策略
應(yīng)對(duì)不同偶聯(lián)ADC的下游高效純化
全球ADC外包市場(chǎng)、如何選擇可靠的CDMO合作伙伴
C3; 質(zhì)量控制及生物分析策略
識(shí)別和研究新型偶聯(lián)位點(diǎn)的快速表征分析
推動(dòng)CQA屬性落地，迎接生產(chǎn)挑戰(zhàn)
解決ADC藥物特殊的生物分析挑戰(zhàn)
復(fù)雜的結(jié)構(gòu)對(duì)生物分析的影響
與時(shí)俱進(jìn)的生物分析工具
ADC藥物的質(zhì)量控制和藥代PK分析策略

中文官網(wǎng)：https://www.bagevent.com/event/adc2024
 
合作聯(lián)系：
演講聯(lián)系人：Ada   18601610075   adaliu@chujietech.com
贊助聯(lián)系人：Wilson  18662147488  wilsonwang@chujietech.com
 
 
EN Version

Event info:
Name：The 5th ADC Development Summit (China Focus)
Location： Suzhou，China
Time： March 1-2，2024

Event Background:
As of October 30,2023, 15 ADC drugs had received approval worldwide.  Promising clinical benefits and significant advancements had been made by the effort from academic and industry since 2018.  For instance, Enhertu a groundbreaking treatment for HER2+ Cancer showing great potential to become blockbuster. The global ADC market in 2022 has grown to US$7.9 billion with a CAGR of 40.4% between 2018 and 2022. Innovation Conjugate platform, optimization of DASs and improved linker together improving ADC precision、clinical efficiency、reduced off-target toxicity。 China's ADC drug development has also successfully attracted investments, cooperation, and licensing out for big pharmaceuticals worldwide.  As for this background, we are going to launch the 5th ADC Development Summit in March 1-2, 2024. Suzhou, China.  We are looking forward to meeting you onsite!
  
Event Topics
Main Forum - Global ADC Investment and Cooperation
ADCs Taking Center Stage
Chinese Collaborations, Approvals and Expansions
The Drivers Behind the Demand for ADCs
A1: Target Selection and Preclinical Research
Novel Biomarkers in ADC
ADC Nonclinical Pharmacology, Toxicology Research and Safety Considerations
Regulatory Perspective of ADC，Nonclinical Safety Assessments
Validated, End-to-End ADC Discovery Platform
Evolving Strategies for Target Selection for ADC
A2: Clinical Development and Beyond Oncology
Global Clinical Trials Challenge
The Strategic Significance and Practice of Clinical Differentiation Development of ADC
ADC Combination Therapy: Combining with Chemotherapy
Exploring ADCs in Solid Tumor and Beyond Streamline the Clinical Path
A3: Next-Generation Conjugates Modalities
Emerging Different Types of Payloads with Novel Mechanism
Increasing Investment for XDC
Better Design and Bring XDC into Clinical
Emerging New Modality ：Degrader-Antibody Conjugates / Peptide Drug Conjugates / Dual-Site or Dual-Target ADCs / Bicycle Radio-Conjugates etc…
B1: Collaboration Between MNC & China Biotech
Wider Therapeutic Window Challenge
Development Progress and Collaborative Challenges Between MNC and Chinese Biotech
Global ADC Drug Development & China Opportunities
Next Cooperation Trend: Expansion of Applications and Treatment lines
Risk Management and Patent Protection
B2: Novel ADC Platform Showcase
Revolutionizing ADC Design: Optimized Antibodies, Cleavable Linkers, Innovative Payloads
Designing Linkers to Increase ADC Efficacy and Reduce Toxicity
Dual-Payload ADCs Using Two Different Cytotoxins to Reduce Resistance
Novel ADC Platform： Payload Diversification
B3: License-out & Commercialization Strategy
Lessons Learned from PD-1 License-Out
Broad Collaborations to Expand Pipelines and Explore Overseas Opportunities
Together With Partner and Communicate with Regulatory Closely for IND Application
Jointly Respond to the Commercial Development of Overseas Markets
C1: Linker & Toxicities and ADC Tolerability
Improve Efficacy, Stability, and Reduce Off-Target Toxicities with Linker Design
Effects of ADC Toxicity and Optimization Strategies
Minimizing Toxicities & Improving Tolerability to Maximize the Tl of ADCs
Immunogenicity, Bystander or Systemic Toxicity, and Rapid Clearance
C2: Process Development with Reliable Partner
Ensuring Your ADC's Product Quality, Identity & Potency
Optimizing ADC Process Development to Deliver on Accelerated Timelines
Engineering, Delivery & Dosing Strategies
Diversification of ADC Formats and Overcoming Purification Challenges
C3: Quality Control and Bioanalytical Strategies
Bioanalytical Strategies for ADC PK Analysis
Rapid Characterization Methods to Identify and Investigate New Bioconjugation Sites
Manufacturing Challenges and Trends
Solving Unique ADC Bioanalytical Challenges State-of-the-art Bioanalytical Tools

Event Website: https://www.bagevent.com/event/ADC2024EN

Contact Us
Speak Opportunity：Ada   18601610075   adaliu@chujietech.com
Sponsor Opportunity：Wilson  18662147488  wilsonwang@chujietech.com